Thermo Fisher Scientific (NYSE:TMO) just crushed expectations, sending its stock up 6.6% this morning as investors cheered a strong Q4 and an even stronger outlook for 2025. Revenue jumped 5% to $11.40 billion, while adjusted EPS climbed 8% to $6.10, beating Wall Street estimates. The company's analytical instruments division led the charge, boosted by new product launches like the iCAP MX Series ICP-MS and Gibco CTS Detachable Dynabeads. Despite flat full-year revenue at $42.88 billion, Thermo Fisher made big movesacquiring Olink, returning $4.6 billion to shareholders, and strengthening its position as the go-to name in life sciences.
Investors are now eyeing what's next. Thermo Fisher projects 2025 adjusted EPS between $23.10 and $23.50, topping expectations. With interest rate cuts easing funding pressure, biotech clients could ramp up spending, giving Thermo Fisher another tailwind. Still, not everyone's convincedDanaher (NYSE:DHR) flagged ongoing caution among smaller biotech firms, though Sartorius (SATG.DE) reported a 23.1% jump in Q4 orders, suggesting demand is picking up. The bigger question: Will this momentum hold, or are we in for some turbulence?
CEO Marc Casper isn't worried. He sees 2025 as a year of growth, fueled by market share gains and deepening partnerships. With $29.06 billion in long-term obligations, Thermo Fisher has to balance aggressive expansion with financial discipline. But if the company executes like it did in Q4, investors betting on its continued dominance might have plenty to look forward to.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。